The immune system enables the body to defend itself against infection. But excessive or inappropriate immune responses can lead to autoimmune diseases, where the immune system attacks the patient’s own tissues. It can also lead to rejection of transplanted organs and to unintended tissue damage in many infectious diseases (including COVID-19).
Currently, the medicines we use to control the immune system across these conditions, for example steroids, are not specific and have effects on many immune cells and other cells in the body, leading to unwanted side effects.
Our Immunity, Inflammation and Transplantation theme will use cutting-edge technologies, profiling the genetic sequence of individual cells in blood and tissue samples taken from patients, to identify new treatments, and to match the right treatment to the right patient.
Antibiotic resistance determination using Enterococcus faecium whole-genome sequences: a diagnostic accuracy study using genotypic and phenotypic data
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial
Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study